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Abstract
Background: As data on the phenotype, characteristics and management of patients with Fragile X Syndrome
(FXS) are limited, we aimed to collect such data in Germany in experienced centres involved in the treatment of
such patients.
Methods: EXPLAIN-FXS is a prospective observational (non-interventional) study (registry) performed between April
2013 and January 2016 at 18 sites in Germany. Requirements for patient participation included confirmed diagnosis
of FXS by genetic testing (>200 CGG repeats) and written informed consent. Patients were followed for up to
2 years.
Results: Seventy-five patients (84.0 % males, mean age 16.7 ± 14.5 years, ranging from 2 - 82 years) were analysed. The
mean 6-item score, determined according to Giangreco (J Pediatr 129:611-614, 1996), was 6.9 ± 2.5 points. At least one
neurological finding each was noted in 53 patients (69.7 %). Specifically, ataxia was noted in 5 patients (6.6 %), lack of
fine motor skills in 40 patients, (52.6 %), muscle tonus disorder in 4 patients (5.3 %), and other neurological disorders in
39 patients (51.3 %). Spasticity was not noted in any patient.
Seizures were reported in 6 patients (8.1 %), anxiety disorders in 22 patients (30.1 %), depression in 7 patients (9.6 %),
ADHD/ADD in 36 patients (49.3 %), impairment of social behavior in 39 patients (53.4 %), and other comorbidities in 23
patients (31.5 %). The mean Aberrant Behaviour Checklist Community Edition (ABC-C) score on behavioral symptoms,
obtained in 71 patients at first documentation, was 48.4 ± 27.8 (median 45.0, range 5-115). The mean visual analogue
scale (VAS) score, obtained in 59 patients at first documentation, was 84.9 ± 14.6 points (median 90; range 50 – 100).
Conclusions: This report describes the largest cohort of patients with FXS in Europe. The reported observations
indicate a substantial burden of disease for patients and their caregivers. Based on these observations, an early expert
psychiatric diagnosis is recommended for suspected FXS patients. Further recommendations include multimodal and
multi-professional management that is tailored to the individual patient’s needs.
Trial registration: The ClinTrials.gov identifier is NCT01711606. Registered on 18 October 2012.
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Background
Fragile X syndrome (FXS) is among the most com-
mon inherited genetic disorders leading to intellectual
disability and autism [1]. It is caused by expansion of
a cytosine-guanine-guanine (CGG) triplet repeat in
the fragile mental retardation 1 (FMR1) gene located
on the X chromosome. The presence of more than 200 re-
peats in the full mutation - compared with 6-44 repeats in
normal individuals – is associated with complete or partial
absence of the fragile mental retardation protein (FMRP),
which regulates neurotransmitter-activated dendritic trans-
lation and synaptic plasticity [2]. While both males and
females can be affected by FXS, in females, the rates of
explicit disease are much lower, and symptoms often
milder, due to the inactivation of only one of the two X
chromosomes in female cells (all females with FXS are
mosaic by definition). A definitive diagnosis can be made
via a simple blood sample test and DNA analysis by
Southern blot or PCR [3].
Reduced intelligence is a major symptom of FXS, vary-
ing from learning difficulties to severe cognitive impair-
ment [4]. Speech, language, and attention deficit occur
frequently [5, 6]. Behavioral problems and mood instabil-
ity often present as the most debilitating aspects of the
disease and reduction in these problems are the pivotal
focus of drug therapy [7]. Other psychopathological syn-
dromes and disorders are also prevalent: up to 50 % of
males with FXS have autistic spectrum disorders [8–10].
Every sixth child with FXS suffers from seizures [11].
Therapeutic options are very limited [12]. The full
spectrum of psychotropic drugs (as per label and off-label)
is utilized for the treatment of attention deficit disorder,
anxiety, hyperactivity, mood swings, anger, depression,
seizures, self-injury, and sleep disorders [13, 14].
Further, non-pharmacological therapy such as speech-
language therapy or occupational therapy is frequently
indicated [15]. In a recent systematic review of 31 inter-
vention studies of individuals with FXS, overall results
suggested that a behavioral approach to intervention
shows promise [16]. Preliminary experience indicates
that assistive technology (i.e. optic sensors such as pho-
tocells) generally may be of use to facilitate employment
and opportunities of choice [17, 18].
Based on their synaptic mechanisms, specific agents in-
cluding arbaclofen, ganaxolone, acamprosate, minocycline,
as well as the mGluR5 inhibitors AFQ056 (mavoglurant
by Novartis) and RG7090 (basimglurant by Roche) have
been investigated in FXS [19, 20]. At the time when the
present study was planned and initiated, the latter two
substances were under investigation in placebo controlled
phase IIb/III studies. However, these were discontinued in
2014 due to lack of efficacy in the FXS indication.
In Germany and other European countries, data on
the phenotype, characteristics, quality of life, caregiver
burden and other aspects of the management of pa-
tients with FXS are limited. The current study aimed
to fill these gaps. It was initiated as a longitudinal
study to investigate changes in psychometric parame-
ters over time.
Methods
Patients
Patients (of all ages and both genders) required con-
firmed diagnosis of FXS by genetic testing (>200
CGG repeats), as well as written informed consent, to
participate. No additional genetic testing was required
for this study.
Patient data were collected at first documentation and
approximately every 6 months thereafter. Patients were
to be followed for at least 2 years. As many patients were
included at a later stage, the duration of follow-up for
these patients was limited.
Study design
The present study is a prospective observational (non-
interventional) study (registry) in Germany. Details of
the study protocol have been reported earlier [21].
The study was conducted in accordance with the local
laws and regulations [22, 23]. The study identifier at
ClinTrials.gov is NCT01711606 (date of registration
18 October 2012).
In 20 % of participating centres, on-site monitoring
of the centres was done with source data verification.
Physicians received remuneration for participation.
Setting
Physicians from about 50 centres (hospitals and phys-
ician practices), all experienced in the management of
FXS, participated in the study. Specialists from other
disciplines were also involved, such as child/adolescent
psychiatrists, general psychiatrists, or physicians in social
paediatric centres.
Variables
At the first documentation visit, data on the following
parameters were documented:
 Demographic data (birth year, gender, height, and
weight)
 Availability of prior genetic testing results (to
confirm FXS diagnosis)
 Status/medical history of relatives (FXS status in
siblings, parents, or other family members; selected
comorbidities in father or mother; educational
degree of parents). No data on premutation in
parents was collected.
 Insurance status (statutory health insurance, private
insurance)
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 FXS patient history (date of diagnosis and symptoms
at diagnosis as measured by the six-item checklist of
Giangreco et al. [24]
 Information on autistic-like behaviour (using the
checklist by Giangreco et al. [24], specifying
characteristics such as tactile defensiveness,
perseverative speech, hand flapping, and poor
eye contact)
 Noteworthy life events in the past six months
(e.g. change of caregiver, relocation, death of
relatives, change of school or workplace)
 Educational status or employment status, as
appropriate
 Comorbid disorders of the patient (seizures, anxiety,
depression, attention deficit disorder, other)
 Neurologic/psychiatric status
 Previous and current medical and non-
pharmacological therapy for FXS
 Symptoms Check List (SCL-27) [25, 26]
 Economic parameters: contacts by physicians
(various specialties), days of hospitalisation since
suspected FXS diagnosis, caregiver’s absence
from work
 Results of psychometric testing:
○ IQ testing: Test of adaptive intelligence
(Adaptives Intelligenz Diagnostikum, AID) [27],
Hamburg-Wechsler intelligence test for children
(HAWIK-R/HAWIE-R) [28], Kaufmann
Assessment Battery for Children (K-ABC) [29],
Snijders Oomen Test [30]
○ Aberrant Behavior Checklist Community
Edition (ABC-C) [31, 32], a proxy-completed
instrument for rating maladaptive and inappropriate
behaviours of individuals with intellectual
disabilities
 Quality of life questionnaires (available as paper
forms in the study file)
○ EQ-5D (adults) [33] or EQ-5D-Y (children and
adolescents) [34], filled out by patient with support
from caregiver
○ Eltern Belastungs Inventar (EBI): German
version of the Parenting Stress Index (PSI)
questionnaire, if caregiver is a family member [35]
○ Nurses’ Observation Scale for In-patient
Evaluation (NOSIE), if caregiver is not a family
member [36, 37]
○ Short version of the International Classification
of Functioning, Disability, and Health (Mini-ICF)
rating for psychiatric disorders [38], filled out by
the caregiver
At the follow-up visits (approximately every 6 months),
information on the following parameters was docu-
mented, in the same manner as at first documentation:
 Noteworthy life events (none, change of caregiver,
change of residence, divorce or marital separation of
parents, death of relative, birth of sibling, starting
school, change of workplace, other)
 Educational status and employment status of the
patient
 current medical and non-pharmacological therapy
 Economic parameters
 Results of psychometric testing (as at the first
documentation visit)
 Quality of life questionnaires (as at the first
documentation visit)
Data on patient history and characteristics were re-
trieved from medical records. Data on quality of life
and psychometric assessments were collected on self-
administered paper forms which were filled out by
the patients and/or their caregivers.
Statistical analysis
The sample size was based on feasibility aspects. The
analysis set consisted of all patients with confirmed FXS
diagnosis included in the study. Data were analysed
descriptively, using established statistical and epidemio-
logical methods. Continuous variables are reported as
median with interquartiles and other percentiles, and as
mean with standard deviation (SD), together with mini-
mum and maximum values. Categorical variables were
reported as absolute values and relative percentages.
Statistical analyses were performed with SAS version 9.2
(Cary, NC, USA).
The authors adhered to the STROBE methodology [39].
Results
Patient characteristics
Of the 76 patients who were screened and found eligible,
75 provided data and were included in the analysis.
Their characteristics are shown in Table 1. The total
number of documented visits was 339 (75.3 % of the 450
maximum total possible visits for the 75 patients).
Of these 75 patients, 63 (84.0 %) were males and 12
(16.0 %) were females. The mean age was 16.7 ± 14.5 years,
ranging from 2 to 82 years. Patients had siblings with FXS
in 17 cases (22.7 %), indicating an extra disease burden on
the afflicted families.
The main caregivers were the parents (or a parent) for
62 patients (82.7 %). Notably, of these parents, 45 were
married (61.6 %) and 6 were not married but living
together (8.2 %).
FXS patients were usually seen by a general practitioner
or a paediatrician. (For example, within the 12 months
preceding first documentation, patients had seen a GP 3.1
times, and a paediatrician 3.7 times).
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The mean 6-item score according to Giangreco (account-
ing for intelligence impairment, family anamnesis, long nar-
row face, large or prominent ears, hyperactivity, and
autistic features) was 6.9 ± 2.5 points.
Impaired intelligence was determined based on
school performance, academic achievement, and IQ
tests. Attendance at a school for children with special
needs was a major criterion for impaired intelligence.
Psychometric tests used at the first documentation were
the Snijders Oomen-Test (10 patients); the HAWIK/
HAWIE (8 patients); the Kaufman Test K-ABC (5 pa-
tients); other (not specified) tests (10 patients).
For the calculation of the Giangreco index (n = 75
patients), 65 patients had an IQ value < 70 points; 8
patients an IQ value of 70 to 85 points; and 2 patients >
85 points. Overall, 73 patients (97.3 %) were deemed to
have impaired intelligence.
Of the 75 patients, 53 suffered from one or more
neurological signs (69.7 %; Table 2). Specifically, ataxia
was noted in 5 patients (6.6 %), lack of fine motor skills
in 40 patients (52.6 %), muscle tonus disorder in 4
patients (5.3 %), and others in 39 patients (51.3 %). Spas-
ticity, defined as spastic paresis or occurrence of pyram-
idal signs, was not noted in any patient.
Comorbidities and treatment
The prevalence of seizures and mental disorders was
high (Table 3). Seizures were reported in 6 patients
(8.1 %), anxiety disorders in 22 patients (30.1 %), depres-
sion in 7 patients (9.6 %), ADHD/ADD in 36 patients
Table 1 Characteristics of patients with FXS and their family members
Number of patients:
Characteristic
≤13 years 14-17 years 18+ years Total (all patients)
40 11 24 75
Age, years 7.7 ± 3.1 15.3 ± 1.1 32.2 ± 16.4 16.7 ± 14.5
range, 2-13 range, 14-17 range, 18-82 range, 2-82
Impaired intelligence 38 (95.0 %) 11 (100.0 %) 24 (100.0 %) 73 (97.4 %)
Sex
Males 35 (87.5 %) 8 (72.7 %) 20 (83.3 %) 63 (84.0 %)
Females 5 (12.5 %) 3 (27.3 %) 4 (16.7 %) 12 (16.0 %)
Siblings
Males 23 (53.5 %) 10 (58.8 %) 16 (47.1 %) 49 (52.1 %)
Females 20 (46.5 %) 7 (41.2 %) 18 (52.9 %) 45 (47.9 %)
Age of siblings in years 8.9 ± 6.2 15.7 ± 7.9 32.6 ± 21.7 18.4 ± 17.5
range, 0-26 range, 1-27 range, 1-85 range, 0-85
Siblings with FXS (genetically validated) 14 (32.6 %) 7 (41.2 %) 19 (55.9 %) 40 (42.6 %)
Other family members with FXS 11 (27.5 %) 5 (45.5 %) 17 (70.8 %) 33 (44.0 %)
Main caregiver: patients living with parent(s) 38 (95.0 %) 9 (81.8 %) 15 (62.5 %) 62 (82.7 %)
Values shown are means ± standard deviation or n (%). Impaired intelligence was determined based on school performance, academic achievement, and IQ tests.
Attendance at a school for children with special needs was a major criterion for impaired intelligence. Psychometric tests used at the first visit were: the Snijders-
Oomen Test (10 patients); the HAWIK/HAWIE-R (8 patients): the Kaufmann Test K-ABC (5 patients); other (not specified) tests (10 patients)
Table 2 Neurological findings
Finding ≤13 years (n = 40) 14-17 years (n = 11) 18+ years (n = 24) Total (all patients, n = 75)
n (%) n (%) n (%) n (%)
At least one of the following 33 (82.5) 9 (81.8) 11 (45.8) 53 (69.7)
Ataxia 4 (10.0) 0 1 (4.2) 5 (6.6)
Spasticity 0 0 0 0
Impaired fine motor skills 26 (65.0) 9 (81.8) 5 (20.8) 40 (52.6)
Muscle tonus disorders 3 (7.5) 1 (9.1) 0 4 (5.3)
Others 24 (60.0) 6 (54.5) 9 (37.5) 39 (51.3)
These conditions were established by treating physicians
Spasticity was defined as spastic paresis or occurrence of pyramidal signs
Multiple answers were possible. “Other” neurological findings were not further specified by documenting physicians
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(49.3 %), and impairment of social behavior in 39
patients (53.4 %). Other comorbidities were noted in 23
patients (31.5 %), of which the following were seen in
more than 1 individual: obesity (5 patients), sleep disorder
(4), foot deformity (3), autism and autism spectrum
disorder (4), and increased infection susceptibility (2). Co-
morbidities were treated with a variety of medications
which are detailed in Table 4. The most frequently noted
drugs were amphetamines and methylphenidate, for the
indications of ADHD and behaviour disorders.
Among non-pharmacological therapies, the following
were noted at first documentation, in descending fre-
quency: speech-language therapy, occupational therapy,
therapeutic pedagogy, osteopathy, music therapy, socio-
therapy, animal assisted therapy, and various other ther-
apies (Table 5).
Life events at first documentation
Relevant life events included change of reference person
to the patient (2 cases, 2.6 %), moving home (5 cases,
Table 3 Prevalence of seizures and mental disorders
Disorder ≤13 years (n = 40) 14-17 years (n = 11) 18+ years (n = 24) Total (all patients, n = 75)
n (%) n (%) n (%) n (%)
Seizures 5 (12.8) 0 1 (4.2) 6 (8.1)
Anxiety disorders 12 (30.8) 3 (27.3) 7 (30.4) 22 (30.1)
Depression 3 (7.7) 1 (9.1) 3 (13.0) 7 (9.6)
ADHD/ADD 24 (61.5) 7 (63.6) 5 (21.7) 36 (49.3)
Impairment of social behaviour 22 (56.4) 6 (54.5) 11 (47.8) 39 (53.6)
Other 11 (28.2) 4 (36.4) 8 (34.8) 23 (31.5)
Suicidality 0 0 0 0
These conditions were established by treating physicians
“Other” disorders were not further specified by documenting physicians
Table 4 Drug treatment of seizures and mental disorders in the 12 months prior to first documentation
Comorbidity category
(n of afflicted patients)
Substance Patient number ≤13 years (n = 40) 14-17 years (n = 11) 18+ years (n = 24) Total (all patients, n = 75)
n (%) n (%) n (%) n (%)
ADH (36) Amphetamine 9 (37.5) 4 (57.1) 1 (20.0) 13 (17.1)
Atomoxetine, Desipramine, etc. 0 1 (14.3) 0 2 (2.6)
Methylphenidate 9 (37.5) 3 (42.9) 1 (20.0) 14 (18.4)
Risperidone, Quetiapine, etc. 3 (12.5) 1 (14.3) 0 6 (7.9)
Other 11 (45.8) 2 (28.6) 1 (20.0) 14 (18.4)
Anxiety (22) Fluoxetine, Fluvoxamine, etc. 5 (41.7) 2 (66.7) 2 (28.6) 9 (11.8)
Amitriptyline, Imipramine, etc. 0 0 0
Diazepam, Lorazepam, etc. 0 0 0
Risperidone, Clozapine, etc. 0 0 2 (28.6) 2 (2.6)
Other 6 (50.0) 2 (66.7) 1 (14.3) 9 (11.8)
Conduct disorders (39) Methylphenidate, Amphetamine, etc. 8 (36.4) 2 (33.3) 2 (18.2) 12 (15.8)
Pipamperone, Melperone, etc. 0 0 0 1 (1.3)
Risperidone, Clozapine, etc. 5 (22.7) 0 2 (18.2) 10 (13.2)
Other 14 (63.6) 4 (66.7) 4 (36.4) 23 (30.3)
Depression (7) Fluvoxamine, Citalopram, etc. 2 (66.7) 1 (100.0) 1 (33.3) 4 (5.3)
Venlafaxine, Bupropion, etc. 0 1 (100.0) 0
Lithium 1 (100.0)
Other 1 (33.3) 0 0 1 (1.3)
Seizures (6) Valproate 1 (20.0) 0 1 (100.0) 2 (2.6)
Other 3 (60.0) 0 1 (100.0) 6 (7.9)
Values indicate patient numbers (n) and, in brackets, the percentage of afflicted patients in the respective age group
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6.6 %), separation of parents (3 cases, 3.9 %), death of a
close person (2 cases, 2.6 %), starting school/work (1 pa-
tient, 1.3 %), and other events (9 patients, 11.7 %). No
such relevant life events occurred in 59 patients (77.6 %).
School type
Fifty one patients (77.3 %) had been attending school,
and 33 of these patients were currently attending school.
Mean duration of school education was 7.7 ± 3.6 years
(range 1- 15). Of these, 32 children and adolescents
(62.7 % of those attending a school) were in a school for
the intellectually disabled, 14 (27.5 %) attended a
similar school type for learning disabled students
(“Förderschule”), 7 (13.7 %) attended a regular school
with integration measures, 2 (3.9 %) attended a regu-
lar school, and 3 (4.9 %) attended a different school
type (none of the above).
Psychometric and sociometric assessments
The 27-item symptom checklist mean score, calculated in
54 patients at first documentation, was 4.7 ± 3.1 points.
The patients had taken various IQ tests prior to
first documentation or took these during the course
of the study.
The Aberrant Behaviour Checklist Community Edition
(ABC-C) score, obtained in 71 patients at first documen-
tation, was 48.4 ± 27.8 (median, 45.0; range, 5-115;
Table 6). At follow-up 1 (in 60 patients) the score was
38.6 ± 23.4 points; at follow-up 2 (in 48 patients), it was
42.0 ± 25.1 points; at follow-up 3 (in 41 patients), it was
43.0 ± 23.1 points; and at follow-up 4 (in 27 patients), it
was 44.3 ± 22.7 points.
The parenting stress index (PSI) total score, obtained
in 64 patients, was 74.6 ± 12.1 (median, 85.0; range, 47
to 85). In the child domain, the mean score was 78.5 ±
10.0 and in the parent domain, it was 65.6 ± 13.2. Over-
all, patients reported a low/normal stress level in 6 cases
(9.4 %), a high stress level in 21 cases (32.8 %), and a very
high stress level in 37 cases (57.8 %). Children reported a
low/normal stress level in 2 cases (3.1 %), a high stress
level in 14 cases (21.9 %), and a very high stress level in 48
cases (75.0 %). In parents, the stress level was lower, and
low/normal stress levels were reported by 25 respondents
(39.1 %), high stress levels by 22 respondents (34.4 %), and
very high stress levels by 50 respondents (78.1 %).
The Nurses’ Observational Scale for Inpatient Evalu-
ation (NOSIE) mean index value, based on answers from
28 patients at first documentation, was 151.5 ± 0.5 (me-
dian, 151.1; range, 151 -153).
Table 5 Non-pharmacological therapy (number of appointments) in the 12 months prior to inclusion
Therapy ≤13 years (n = 40) 14-18 years (n = 11) 18+ years (n = 24) Total (n = 75)
n mean n mean n mean n mean
Psychotherapy 9 5.1 ± 13.2 0 - 11 2.6 ± 7.5 20 3.8 ± 10.2
Occupational therapy 23 30.6 ± 17.9 9 25.9 ± 17.6 11 - 43 21.8 ± 19.9
Speech therapy 32 30.8 ± 17.2 4 37.0 ± 29.1 9 1.1 ± 3.3 45 25.4 ± 20.5
Sociotherapy 8 5.0 ± 14.1 1 30.0 9 - 18 3.9 ± 11.4
Therapeutic pedagogy 18 21.4 ± 20.4 1 20.0 10 4.0 ± 12.6 29 15.3 ± 19.4
Music therapy 10 14.0 ± 19.0 1 40.0 9 0 20 9.0 ± 16.5
Osteopathy 10 0.9 ± 1.5 1 2.0 10 0.3 ± 0.9 21 0.7 ± 1.3
Animal-assisted therapy 3 0.0 ± 0.0 0 - 4 - 7 0.0 ± 0.0
Other 29 39.7 ± 35.6 4 15.3 ± 18.9 10 4.0 ± 12.6 43 29.1 ± 33.9
Table 6 ABC Community score at first documentation
≤13 years (n = 40) 14-17 years (n = 11) 18+ years (n = 24) Total (all patients, n = 75)
Score/ subscores
Total score 55.4 ± 29.7 48.5 ± 23.0 36.4 ± 23.1 48.4 ± 27.8
Irritability 18.4 ± 11.8 15.4 ± 11.6 9.1 ± 7.6 15.0 ± 11.3
Lethargy 7.7 ± 6.2 6.4 ± 5.1 6.9 ± 7.1 7.2 ± 6.3
Stereotypic behaviour 6.6 ± 4.9 5.1 ± 4.8 3.4 ± 3.3 5.4 ± 4.6
Hyperactivity 13.5 ± 7.7 8.7 ± 5.7 7.4 ± 6.5 10.9 ± 7.5
Inappropriate speech 4.1 ± 3.4 5.9 ± 3.4 4.1 ± 3.7 4.4 ± 3.5
Social avoidance 3.6 ± 3.0 6.0 ± 3.3 3.9 ± 3.6 4.0 ± 3.3
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On the mini-ICF, the average value at first documenta-
tion, obtained in 73 patients, was 2.2 ± 0.8 (median, 2.2;
range, 0 to 4).
EuroQol 5D-3 L
The EQ-5D index in adults at first documentation, ob-
tained in 41 patients, was 0.7 ± 0.3 points (median, 0.7;
range, 0-1). The EQ-5D index in children at first docu-
mentation, obtained in 22 patients, was 0.7 ± 0.3 points
(median, 0.8; range, 0-1). The EQ-5D time trade-off
value in adults at first documentation, obtained in 22
patients, was 0.8 ± 0.3 points (median, 0.9; range, 0-1).
The EQ-5D time trade-off value in children at first
documentation, obtained in 41 patients, was 0.7 ± 0.3
points (median, 0.9; range, 0-1). On the EQ-5D visual
analogue scale (VAS), the mean value at first documen-
tation, obtained in 59 patients, was 84.9 ± 14.6 points
(median, 90; range, 50 - 100).
Discussion
The EXPLAIN study is the largest and the only longitu-
dinal European observational study investigating clinical
characteristics and caregiver situation of patients with
FXS. It documents 75 individuals in a wide age range,
from 2 to 82 years. As expected, the prevalence of
neurological findings and other comorbidities was very
high. Almost every patient in our study had a relevant
mental or neurological disorder which required pharma-
cological or non-pharmacological treatment. In younger
patients, externalizing symptoms prevailed; in older pa-
tients, internalizing symptoms prevailed.
The only systematic recording of data on patients
with FXS is currently taking place in the USA, in the
context of individual projects, namely by the Fragile
X Clinical & Research Consortium (FXCRC), with its
FORWARD Registry and Database, and by our Fragile
X World Surveys (twice per year, also supported by
the U.S. Centers for Disease Control) [14, 15, 40].
The majority of documented patients in the present
study were children and adolescents; only 29 were
adults. Thus, it is understandable that most patients
were still living with their parents, who mostly were the
main caregivers. This indicates solid family structures, and
might be a finding based on patient selection. The proxy
information collected in this study can be considered to
be “first-hand” and very reliable.
In light of the common social and behavior problems
linked with FXS, an important tool for our study was the
ABC-C questionnaire. It is a sensitive instrument for
rating maladaptive and inappropriate behaviors in pa-
tients with intellectual disabilities. In patients with FXS,
it has also been used as an endpoint in clinical studies
(in the original or a modified version) [41–43]. For
example, in the mavoglurant studies, mean total scores
at first documentation were, across the placebo and
treatment groups, between 40.0 and 50.6 points in
adults, and between 48.3 and 58.5 points in adolescents.
The corresponding scores in our study were substan-
tially lower in adults (36.4 points), and similar in adoles-
cents (48.5 points). During the study, we found small
improvements in the ABC-C score which remained
constant over time. This might represent a study artefact
or a nonspecific benefit of study participation.
The study shows a high burden of comorbidities as
well as mental symptoms. The rates of mental health
symptoms, at least in children and adolescents, were
higher than the prevalence of such symptoms in the
general population of individuals with intellectual dis-
ability in this age range. The prevalence of mental health
symptoms in the general population of individuals with
intellectual disability has been documented as follows:
24 % with impaired social behavior; 13 % with emotional
problems; and 26 % with hyperactivity [44]. In EXPLAIN,
the prevalences were 53.6 %, 39.7 %, and 49.3 %, respect-
ively. As autistic behaviors were not specifically assessed
in EXPLAIN, no conclusions can be drawn about them.
However, overall, 42 % of parents and other caregivers
reported such symptoms in their patients without describ-
ing them in detail. This prevalence is comparable with
international studies reporting a prevalence of autistic
symptoms between 25 and 47 % [45].
Compared with another study in a large US American
cohort (89 women and 239 men aged between 22 and
64 years) [46], affective symptoms were less frequent in
the adults (71.7 % versus 43.4 %). Hyperactivity in this
age range occurred in only 21.7 %. Conversely, Hartley
et al. described hyperactivity in 64.3 % of adults with
FXS [46].
It was an unexpected finding that the comorbid men-
tal health symptoms and diseases usually were treated
with medications. Usually the prescription of psycho-
pharmacological drugs in individuals with impaired
intelligence is between 21 and 45 % [47]. The high pre-
scription prevalence is probably an indicator of the
severity of the individual disorder. Usually, for patients
with FXS, findings from other neurodevelopmental disor-
ders such as autism or other forms of intellectual disability
are extrapolated for therapy planning [48–50]. The
FXCRC has highlighted that this patient group is sensitive
to psychotropic medication, and recommends low doses
and cautious titration [51].
In terms of quality of life assessment, as expected, pa-
tients with FXS had limitations in terms of self-care
and usual activities, but also anxiety/depression. Com-
pared with the German reference population [52], pa-
tients with FXS reported similar values for general
health (visual analog scale). The EQ-5D questionnaire
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is widely used in studies with adults as a source of
generic health-related quality of life information and
utility weights to inform resource allocation decisions.
Despite methodological limitations, the EQ-5D in its
“youth” form is suitable for the same aim in children
[34, 53]. On the EQ-5D scale, the EQ-5D time trade off
(TTO) consists of a hypothetical trade-off between a
shorter lifespan and a healthier quality of life. The
respective reference score for the FXS population was
calculated as described by Greiner et al. [33] The utility
index value (0.8) was high, but showed substantial vari-
ation between patients. It remained relatively constant
across the follow-up visits.
As a limitation to this study, a number of instruments
which were used in other FXS studies were not applied in
our study. For example, the mavoglurant studies had
applied, among others, the SRS scale to identify the pres-
ence of autistic social impairment; the TEA-Ch to test
every-day attention and inhibition in children; or the
widely used Clinical Global Impression (CGI) scale to
assess treatment response in psychiatric patients [42]. This
study might be prone to selection bias: [54] participating
centres might represent a positive selection with particular
interest in FXS (and research questions). Participating pa-
tients (or their caregivers) might be more likely than others
to understand the disease and to contribute to the
optimization of management. Finally, we did not collect
information on associated non-neurological medical prob-
lems which are known to be frequent among patients with
FXS (such as otitis media, gastrointestinal problems and
obstructive sleep apnea), and which increase the propensity
for many behavioural problems [55].
Conclusion
In conclusion, the findings in EXPLAIN-FXS confirm
the substantial burden of psychiatric and mental prob-
lems in patients with FXS in all age groups. In these
patients, an early expert psychiatric diagnosis should be
initiated. The resulting management should be multi-
modal and multi-professional and should be tailored to
the individual patient’s needs.
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